Eli Lilly and Company $LLY Position Decreased by MFG Wealth Management Inc.

Key Points

• MFG Wealth Management Inc. has reduced its holdings in Eli Lilly and Company by 23.0%, now owning 2,097 shares valued at approximately $1,635,000.
• Insider transactions included Gabrielle Sulzberger and J Erik Fyrwald, who together acquired over $1 million worth of shares, indicating a positive outlook on the stock.
• Eli Lilly reported strong quarterly earnings with $6.31 EPS, surpassing expectations and setting its FY 2025 guidance at 21.750-23.000 EPS.

MFG Wealth Management Inc. decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 23.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,097 shares of the company's stock after selling 627 shares during the period. MFG Wealth Management Inc.'s holdings in Eli Lilly and Company were worth $1,635,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in LLY. WestEnd Advisors LLC boosted its position in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company in the first quarter worth approximately $27,000. Citizens National Bank Trust Department increased its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company in the first quarter worth approximately $40,000. Finally, Mascagni Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $43,000. Institutional investors own 82.53% of the company's stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 in the last three months. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $748.26 on Tuesday. The stock has a 50-day simple moving average of $740.54 and a 200 day simple moving average of $774.30. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $939.86. The stock has a market capitalization of $708.20 billion, a price-to-earnings ratio of 48.91, a P/E/G ratio of 1.05 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were given a $1.50 dividend. The ex-dividend date was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is currently 39.22%.

Analyst Ratings Changes

Several research firms have recently weighed in on LLY. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Leerink Partners reissued a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. HSBC raised shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their target price for the stock from $675.00 to $700.00 in a research report on Wednesday, August 27th. Wall Street Zen raised shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. Finally, Cantor Fitzgerald decreased their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $941.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.